Glenmark launches fixed dose combination drug for diabetes in India
[ad_1]
The firm has launched the product below two model names — Remo V and Remozen V
Glenmark Pharmaceuticals on Tuesday stated it has launched a fixed-dose combination drug for the therapy of Type 2 diabetes in the nation.
It has launched a fixed-dose combination of Remogliflozin Etabonate and Vildagliptin in India for the administration of Type 2 diabetes, the Mumbai-based firm stated in an announcement.
The drug accommodates Remogliflozin (100 mg) and Vildagliptin (50 mg) in a fixed-dose and should be taken twice day by day to enhance glycemic management in sufferers, it added.
The firm has launched the product below two model names — Remo V and Remozen V — in the nation.
“Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed-dose combination and India is the first country to get access to this FDC drug,” the drugmaker stated.
The firm had acquired approval for the product from the DCGI in late November.
While the common day by day value of remedy of present manufacturers in the identical drug class is ₹78, Glenmark”s Remogliflozin-Vildagiptin combination has been launched at ₹14 per pill, to be taken twice day by day; which quantities to ₹28 because the per-day value of the therapy, Glenmark stated.
This value is 65% decrease than the opposite obtainable SGLT2 and DPP4 combination medicine in the market, it added.
“We are glad to introduce this innovative fixed-dose combination, which is cutting-edge, extensively researched, and at an affordable cost for patients in the country,” Glenmark Group Vice President and Business Head India Formulations Alok Malik stated.
Diabetes is a key space of focus for the corporate and the launch of this product will allow it to enhance entry to diabetes therapy by offering an efficient and reasonably priced therapy choice to sufferers in India, he added.
Globally, SGLT2 inhibitors (Sodium-Glucose Co-Transporter Inhibitor) and DPP4 inhibitors (Dipeptidyl Peptidase 4 inhibitor) are rising as the popular therapy choice for the administration of Type 2 diabetes.
According to the International Diabetes Federation, there have been round 77 million adults in India dwelling with diabetes as of 2019.
